Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich
zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
NEJM Journal Watch Oncology and Hematology Top Stories of 2024
Dear Readers,
The past year highlighted the wide application and clinical utility of immunotherapy as a component of systemic therapy across a wide variety of malignancies, both in early- and late-stage disease. Additionally, understanding the mutational makeup of a tumor has informed the use of targeted therapy in aggressive breast cancers and non–small-cell lung cancer. Chimeric antigen receptor T-cell therapy has been shown to positively impact outcome in mantle cell lymphoma. Finally, assessing ferritin levels in blood donors may decrease the risk of iron-deficiency compared with simply assessing hemoglobin levels.
The top NEJM Journal Watch Oncology and Hematology stories for 2024 are:
Sotorasib plus Panitumumab for Mutated KRAS G12C Metastatic Colon Cancer
Paradigm Shift in the Management of Advanced Urothelial Cancer
CAR T-Cell Therapy for Mantle-Cell Lymphoma
Ferritin-Guided Blood Donation: A Better Way to Prevent Anemia in Blood Donors?
A New Standard of Care for Limited-Stage Small-Cell Lung Cancer?
More Support for Adding Pembrolizumab to Chemotherapy and Surgery in Triple-Negative Breast Cancer
Nivolumab+AVD or Brentuximab Vedotin+AVD in Advanced-Stage Hodgkin Lymphoma?
Triplet Therapy for Bad-Acting ER+ Breast Cancer
Perioperative Durvalumab for Muscle-Invasive Bladder Cancer?
First-Line Immune Checkpoint Inhibitor Therapy for MSI-High Metastatic Colon Cancer
Betibeglogene Autotemcel Gene Therapy for Transfusion-Dependent β-Thalassemia
Empfohlen von
William J. Gradishar, MD